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Abstract: Alzheimer’s and Parkinson’s diseases are the two most common forms of neurodegenerative diseases. The exact etiology of these disorders is not well known; however, environmental,
molecular, and genetic influences play a major role in the pathogenesis of these diseases. Using
Alzheimer’s disease (AD) as the archetype, the pathological findings include the aggregation of
Amyloid Beta (Aβ) peptides, mitochondrial dysfunction, synaptic degradation caused by inflammation, elevated reactive oxygen species (ROS), and cerebrovascular dysregulation. This review
highlights the neuroinflammatory and neuroprotective role of epigallocatechin-3-gallate (EGCG): the
medicinal component of green tea, a known nutraceutical that has shown promise in modulating
AD progression due to its antioxidant, anti-inflammatory, and anti-aging abilities. This report also
re-examines the current literature and provides innovative approaches for EGCG to be used as
a preventive measure to alleviate AD and other neurodegenerative disorders.
Keywords: Alzheimer’s disease (AD); inflammation; oxidative stress; microglia; aging and
epigallocatechin-3-gallate (EGCG)
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The global burden of neurodegenerative ailments increases due to aging populations,
longer lifespan, and changing environments. The world health organization (WHO) has
shown that neurological diseases constitute 12% of total global mortality and contribute
to 16.8% of total deaths in lower-middle and 13% in high-income countries [1]. By 2030,
neurological diseases, AD, and other dementias will contribute 38% of global disability,
as calculated as years of life lost due to disability [1]. The World Health Organization
reported that in 2015 the international cost of dementia was projected to be USD 818 billion
(approximately 1.1% of global GDP) [2]. Neurodegenerative diseases, such as Huntington’s disease (HD), Parkinson’s disease (PD), multiple sclerosis (MS), amyotrophic lateral
sclerosis (ALS), and Alzheimer’s disease (AD), are caused by different etiological factors,
including environmental, molecular, and genetic factors. Various hallmark determinants of
neuro-degenerative diseases’ pathogenesis include inflammation, elevated reactive oxygen
species (ROS), aging, and epigenetic instability.
Alzheimer’s disease was first identified in 1906 by a German physician and pathologist
Alois Alzheimer who was able to identify plaque formation and neurofibrillary tangles in
his 51-year-old female patient. Still, it was not until 70 years later that a better understanding
of its causes, processes, and properties was ascertained [3]. The nervous system is highly
susceptible to neurodegeneration because it is anatomically isolated, requiring substantial
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2.1. Parkinson’s Disease (PD)
The most extensively studied neurodegenerative ailments have been PD and AD.
PD is widespread in aging populations (individuals over age 65) and is second only to
AD in its incidence. It involves neuronal death in the substantia nigra, which results in
striatal dopamine deficiency and Lewy bodies: intracellular debris containing fragments
of Alpha-synuclein (αS; α-synuclein) [8]. The symptoms of PD are resting tremor, rigidity,
bradykinesia, gait difficulty, and postural instability; nonmotor symptoms include depression, anxiety, emotional changes, cognitive impairment, sleep difficulty, and olfactory
dysfunction [9]. Research has shown that neurodegeneration in the substantia nigra region
is due to the reduction of neuromelanin, as shown by the loss of dark grey pigment in this
area [10]. Physiological changes of dopaminergic neurons due to aging result in a decrease
in dopamine levels and loss of expression of the dopaminergic phenotype [11]. Other
non-dopaminergic neurons interconnected with dopaminergic neurons are also affected,
such as cholinergic neurons of the pedunculopontine nucleus and glutamatergic neurons
of the intralaminar thalamic nucleus.
PD’s association with microglia and neuroinflammation comprises overactive microglia that can also release countless amounts of cytokines and chemokines, leading
to neurodegeneration aging [12,13]. New scientific investigation shows that αS serves
a dual role as a pathological progenitor in its role in protein aggregation, but also aids
in normal immune function [13–15]. PD, similar to AD, shows the consequences of the
aging brain [16]. To date, epigenetic alterations of DNA methylation caused by aging also
contribute to neurodegeneration, which is displayed in both AD and PD pathologies [16].
The pathogenesis of Parkinson’s disease involves not only aging and genetics, but also
environmental factors such as cigarette smoking and exposure to pesticides [11]. These
have been linked to causing mitochondrial dysfunction resulting in the PD pathology. Neurotoxins in the brain can result in oxidative stress and neurotransmission stagnation, which
can have detrimental effects in the basal ganglia [17]. The production of reactive oxygen
species (ROS) occurs when hydroxyl radicals are generated from hydrogen peroxide under
the Fenton Haber Weiss reaction. This reaction may cause oxidative stress and neurotoxicity to various cellular compartments, primarily affecting the mitochondria via hydroxyl
radicals, which respond to deoxyribonucleic acid (DNA), membrane lipids, and proteins
of the cell, contributing to their eventual dysfunction. The latest treatments available are
Levodopa therapy that, if combined with carbidopa, shows promise as a peripheral dopa
decarboxylase inhibitor. The other therapy is the use of dopamine agonists, catechol-omethyl-transferase (COMT) inhibitors, anticholinergics, and monoamine oxidase inhibitors
(Mao-B). Subthalamic stimulation is recommended only for the clinically and biologically
fit [18].
2.2. Alzheimer’s Disease (AD)
AD is the most prevalent neurodegenerative disease that affects more than 35 million
worldwide (5.5 million in the U.S.). The prominent risk factor is aging, which doubles every
five years after 65 and an increase in predominance of the disease (13.2–16 million cases in
the United States) by mid-century [19]. African Americans (AA), Latinos, and Hispanics
are more susceptible to cognitive impairment and delayed onset compared to Caucasians
due to the prevalence of cardio/cerebrovascular disorders, genetics, socioeconomics, and
racial/ethnic discrimination [20].
AD is a genetically complex disorder, and more than 100 rare mutations have been described [21]. AD has genetic determinants in the form of the early onset (EOAD) or familial
AD (FAD), which involves the mutation of one of three genes, amyloid precursor protein
(APP), presenilin 1 (PSEN1), or presenilin 2 (PSEN2). These genetic alterations allow for
the early development of AD (30–50 years of age). Although it is a rare (affecting less than
1% of all AD cases) autosomal dominant inherited form of AD, it has enhanced scientific
knowledge about AD development and pathology (particularly neurofibrillary tangles
and tau hyperphosphorylation). APP is the most widely studied due to its involvement

Biomolecules 2022, 12, 371

4 of 34

with amyloid-beta, but the presenilins are significant fragments of the atypical aspartyl
complexes that function in the cleavage of γ-secretase to APP, and PSEN1 is responsible
for EOAD [22]. The other form is sporadic or late-onset AD (LOAD), which is nondominant and involves the allele Apolipoprotein ε4 (APOE4), which accounts for 95% of AD
incidents [23–25]. APOE ε4 has been linked to a greater risk of AD in patients with Down
Syndrome, traumatic brain injury, and stroke. It has also been linked with metabolic risk
due to its responsibility in cholesterol/triglyceride metabolism [22]. APOE adheres to definite receptors, i.e., LDL receptor-related protein 1 (Lrp1) and very-low-density lipoprotein
receptor (VLDLR), that expel chylomicron and VLDL residue from circulation, allowing for
normal triglyceride-rich lipoprotein catabolism [26,27].
Many hypotheses have been proposed for AD’s origin—the cholinergic, Aβ, and
inflammation hypothesis. The amyloid cascade hypothesis suggests that neurodegeneration
arises due to a sequence of events activated by the abnormal processing of the amyloidbeta precursor protein (APP) [8,28]. The cholinergic hypothesis suggests that cholinergic
instability leads to AD pathology. Meanwhile, the neuronal cytoskeletal degeneration
hypothesis indicates that cytoskeletal changes are the cause. Furthermore, the metal theory
postulates that metal ions are responsible for AD genesis. Moreover, inflammation has been
related to microglial activation, reactive astrocytes, and heightened cytokine expression,
leading to AD [29].
The theory behind the inflammation link to AD is that inflammatory processes of one
system are synonymous with those of another system. The inflammatory regulators seem
to be enhanced in areas of high AD pathology (such as the frontal neocortex and limbic
cortex). Furthermore, stimulated microglia and reactive astrocytes aggregate near fibrillar
plaques. Chronically stimulated microglia release chemokines and lead to a sequence of
events of damaging cytokines, i.e., interleukins IL-1, IL-6, and tumor necrosis factor-α
(TNF-α). Microglia contain receptors for higher-level glycation end products, which bind
Aβ resulting in boosting the generation of cytokines, glutamate, and nitric oxide (NO).
Microglia also dislodge Alpha-1-antichymotrypsin (ACT), alpha-2-macroglobulin (A2M),
and c-reactive protein (CRP), which can intensify AD [30].
One of the main clinical attributes of AD is protein aggregation in the form of extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles (NFT). Patients
exhibit prolonged cognitive decline, which presents itself as lapses of time and forgetfulness. It can continue to affect speech, higher-order reasoning, visuospatial abilities, and
behavioral changes. In the later stages, the patient loses total ability to perform rudimentary activities such as eating, toileting, and dressing, resulting in complete reliance upon
a caregiver. Current diagnosis is based on patient history evaluation that assesses mental
state via a cognitive function test and physical examination that examines vascular and
neurological signs. Current drug treatment for AD has been limited due to a dearth of
effective biomarkers, complicated clinical trial designs, indefinite clinical measurements,
hindered differentiation from other dementias, hampered focus on treating the underlying
origin of CNS disease, and deficiency of predictive animal models [31].
In light of these facts, the therapeutic strategies are mostly symptomatic treatments
with non-steroidal anti-inflammatory drugs (NSAIDs) shown to decrease the risk of AD and
delay progression, but only in prospective observational studies by halting cyclooxygenase
2 (COX-2) or the prostaglandin E2 receptor, activating phagocytosis by microglia, triggering peroxisome proliferator-activated receptor gamma (PPAR-γ), and selective decrease
of Aβ42 [19]. The Food and Drug Administration (FDA) approved acetylcholinesterase
inhibitors (AChEI) (rivastigmine and donepezil) and NMDA receptor antagonist (Memantine) drugs have been utilized to alleviate the cholinergic and glutamatergic disintegration/excitotoxicity, respectively, leading to synaptic disruption caused by the AD
pathology [32–34]. Present therapeutics are disease-modifying agents mainly focused on
the Aβ propagation, but they have failed in clinical trials [35]. Other targeted strategies
are sirtuins (SIRT), which have recently been associated with age-related diseases, and
caspases, which are involved in apoptosis and autophagy [36]. Recently, more studies
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have focused on preventing the risk factors and co-morbidities, in particular, diet and
obesity [37], cerebrovascular (the brain renin-angiotensin system (RAS) [38]), and energy
dysregulation [39].
2.3. Protein Aggregation in AD: The Role of Amyloid Beta (Aβ)
Extensive research has linked APP with AD pathogenesis [40]. The adhesion to APP
occurs in two unique ways: α-secretase, a proteolytic enzyme that triggers the nonamyloidogenic pathway, which leads to APP joining within the Aβ region, resulting in Aβ
generation. Adherence of APP by α-secretase generates α-secreted APP (sAPPα) and
the leftover fragment C terminal (α-CTF). The other route involves the BACE-catalyzed
β-attachment of APP promoting Aβ formation and the amyloidogenic pathway. BACE
cleavage produces β-secreted APP (sAPPβ) and the c-terminal fragment β-CTF of APP.
The c-terminal remnants (α and β CTF) are substrates for γ-secretase, a universal multimeric protease. The binding of α-CTF to γ-secretase yields a shortened nonamyloidogenic
peptide (p3). However, β-CTF adherence promotes Aβ propagation. Aβ is evidence of the
main proteinous remnant of amyloid plaques in the AD brain [41].
The APP intracellular domain (AICD) is generated in both the amyloidogenic and
nonamyloidogenic pathways via the joining of γ-secretase. Most amyloid-beta remnants
are Aβ40 in length; however, the elongated Aβ 42 variant is the most pathogenic. A possible inference is that the continuous assembly of Aβ oligomers causes synaptic damage
culminating in neurodegeneration [3]. The latest research has shown that Aβ can activate microglia and promote a chronic inflammatory state resulting in unregulated proinflammatory cytokine release, leading to neurodegeneration [42,43]. Alasmari et al. [40]
demonstrated that proinflammatory cytokines could mediate Aβ neurotoxicity via APP
protein homeostasis/metabolism. Aβ has also been linked to causing iron dyshomeostasis,
stimulating oxidative stress in microglia leading to neurodegeneration [44,45].
2.4. Tau Protein: Neurofibrillary Tangles and Aggregation in AD
Tau is related to a family of microtubule-associated proteins (MAPs) that reside mainly
in neurons, function to support microtubules, and aid in proper cellular trafficking and
cytoskeleton scaffolds for cells. Tau protein contributes to the formation of neurofibrillary
tangles due to impaired oxidative phosphorylation or apoptotic function [46]. Tau becomes
pathological due to hyperphosphorylation that occurs due to unstable kinase and phosphatases acting on the tau protein [47]. The phosphorylation of tau has been associated
with N methyl D aspartate receptor (NMDAR) at postsynaptic locations, which may be
related to the synaptic instability that occurs in PD [48]. The mechanism of filament aggregation that occurs in tau is still being investigated. The process of fibrillogenesis (similar
process to Aβ fibrillogenesis) has been postulated as one of the mechanisms. First, protein
dimerization occurs through the arrangement of disulfide bridges or through ionic bonds;
then, a nucleation phase follows, in which the dimers self-assemble to generate oligomers;
lastly, the elongation phase occurs in which the oligomers thicken. Tau autosomal dominant
mutations in microtuble associated protein (MAPT), the gene encoding for tau, were found
to cause frontotemporal dementia with parkinsonism (FTPD-17 mutation) [49].
3. Role of Inflammation
Current research has led to neuroinflammation as being a prominent factor in the
genesis of neurodegeneration. The innate immune response to viral infection or traumatic
brain injury induces glial cell activation, i.e., microglia and astrocytes, essential for immunoregulative central nervous system (CNS) homeostasis [50]. This regulation is carried
out in a series of processes conjunctionally between the microglia and astrocytes, leading to
neurodegeneration at various molecular intervals involving cell death mediation, synaptic
remodeling, as well as immune-signaling regulation, i.e., (a) apoptosis, (b) necroptosis, (c)
autophagy, (d) retrograde degeneration, (e) Wallerian degeneration, (f) demyelination, and
(g) astrogliopathy [51].
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The complement system serves as a pivotal pathway of regulating the interplay of
acute vs. chronic neuroinflammation within the CNS microenvironment and links to understanding CNS immunoregulation [52–54]. Neuroinflammation is normally beneficial
for the proper control of external stressors. Still, it can become detrimental when the
immune response is prolonged (or chronic) due to immunosenescent aging, which leads to
immune signaling dysregulation culminating in neurodegenerative pathogenesis [55,56].
De Oliveira et al. [57] discuss the disruption of natural energy (mitochondrial) homeostasis by the mitochondrial damage-associated molecular patterns (mDAMPs), which can
lead to receptor-mediated (NOD-like receptor (NLR) and TLR) cascade of inflammatoryimmunological response. Continued research is focused on the relationship between
chronic inflammation and AD.
3.1. Microglia and the Debilitating Effects Caused by Aging
Microglia are specialized macrophages of the CNS. Microglia function in surveillance
of the CNS microenvironment through six divisions: (1) proliferation, (2) morphological
transformation, (3) motility and migration, (4) Intercellular communication, (5) phagocytosis, and (6) proteostasis. Microglia differ from other glial cells, such as astrocytes, by their
hematopoietic origin and main responder to pathogen infection and injury [58]. Microglia
contain many macrophage-associated markers, i.e., CD11b and CD14. These cells are activated by either the classical or alternative complement system; classically, microglia become
activated due to pathogen invasion and initiate the major histocompatibility complex II
(MHC-II), which recruits T cells and other proinflammatory mediators. They also contain
many receptors that function in surveillance, such as the pattern recognition receptors (Tolllike receptors (TLRs)), retinoic acid-inducible gene-I-like receptors (RIG-1 like receptors),
and nucleotide-binding oligomerization domain-like receptors (NOD-like receptors). Protein recognition receptors (PPRs) sense pathogen recognition molecular patterns (PAMPs),
whereas TLRs detect damage-associated molecular patterns (dAMPs) [59,60].
In AD, progression seems to render microglial cells less efficient in degrading these
dense aggregates [61]. Microglia also contain many other receptors, such as ion channels, that aid in microglial recognition of disease-associated molecular patterns (DAMPs)
expelled from damaged or necrotic cells and serve a role in the clearance of debris and
stimulation of tissue repair after CNS injury, such as purinergic receptor and receptor for advanced glycation end products (RAGE). The purinergic P2 purinoreceptors are categorized
into two subgroups: ionotropic receptors (P2X receptors), which create ion channels that
are opened by adenosine triphosphate (ATP) and metabotropic receptors (P2Y receptors),
which bind purines or pyrimidines and initiate downstream signaling events through
G-protein coupled receptors (GPCRs) [62]. Nucleoside triphosphates (NTPs) expelled
from injured cells can attach to P2X or Y receptors and stimulate the proinflammatory
transcription mediators via the transcription factor, nuclear factor kappa B (NF-κB), and
activator protein I (AP1). Microglia have also been shown to crosstalk with astrocytes and
intensify the immune response. Microglia is a crucial factor in neurovascular maturation
and is involved in angiogenesis [63]. This role has allowed for extensive research in its
association with various diseases related to the brain, such as ischemic stroke, brain tumors,
and neurodegenerative disorders.
Aging causes a gradual reduction in physiological functions and behavioral capabilities, which is displayed at many phases of the organism, especially in the CNS [64].
Microglia experience many age-related transformations that advance to promoting a chronic
mild inflammatory environment, i.e., elevated production of inflammatory cytokines and
ROS. Research has shown that the normal brain mass atrophies 2–3% per decade after
50 [64]. Using magnetic resonance technology (MRT) and voxel-based morphometry, atrophies were present mainly in the gray and white matter volume changes in the prefrontal,
parietal, and temporal areas. Furthermore, complex learning functions are diminished
with age. At the cellular level, aging leads to shrinking telomeres and initiation of tumor
suppressor genes, compiling DNA damage, oxidative stress, and imbalance of pro- and
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inhibitory inflammatory cytokine activity. Mosher and Coray [65] made the important
statement, “The hallmarks of microglial aging may also sometimes be characterized as
dysfunctional and even hyper-reactive responses.” It has been postulated that cumulative
stimulation in response to systemic infections over the course of a lifetime leads to systemic
inflammation, causes the cells to be hyperactivated, and aids in neurodegeneration. In addition, an increase in the engineering of ROS via permeability of the blood-brain barrier
(BBB) leads to deterioration of neurons and other brain cells and heightened systemic
inflammation [65].
Research has shown that microglia proliferation and self-renewal increases with age.
Still, it is believed that this progressive assembly of microglia is a compensatory mechanism
to sustain the necessary level of protection from the overall microglial population as the
individual cells become less capable with age [65]. Morphological changes in AD show
that microglia have short, thick, and poorly ramified processes [65]. Microglial motility is
reduced with age and display diminished reactions to exogenous ATP and laser-induced
focal tissue injuries. Aged microglia display overexpression of many pro-inflammatory
markers, such as MHCII, antigens, CD11b/CR3, and CD14. It has also been shown that
normal mediators of microglial activation and inflammatory responses are curtailed due
to aging [66]. Microglia normally modulate the phagocytotic processes involved in the
immune system. Still, aging diminishes these processes as evidenced in dysregulated
proteostasis pathways that involve a disruption in chaperone-mediated protein folding
and stability, protein trafficking, protein breakdown, autophagy, and compiling of proteins
in AD [65].
3.2. Microglia and Tau
Senescence of microglia manifests itself as morphological alterations, cytokine expression, phagocytosis, stimulation, and density [67]. Ongoing inquiry shows that microglia
may be responsible for the synaptic and non-synaptic circulation of pathological tau. Microglia envelop both soluble and insoluble states of tau. The envelopment of tau allows for
either tau degradation or release in exocytosing microvesicles known as exosomes in which
elevated levels are situated in the CSF and blood of AD patients [68]. Further postulation is
that dephosphorylated tau contributes to microglial neurotoxicity [69].
4. Neuroinflammatory Mediators
Cognitive disruption due to cytokine/chemokine regulated associations between
CNS neuronal bodies has been thoroughly researched [70]. AD pathology leads to the
overexpression of these mediators resulting in enhanced plaque formation and neuronal
cell deterioration [70]. Inflammatory regulators involved in AD are as follows: (1) tumor
necrosis factor-alpha (TNF-α), (2) interleukin (IL)-6, (3) interferon-gamma (IFN)-γ, (4)
inducible protein-10 (CXCL10), (5) monocyte chemoattractant protein 1 (MCP-1), and (6)
C-X-C motif ligand (CXCL-8). Interleukin 6 (IL-6) regulates numerous immune reactions
affecting CNS cell development and cellular diversity by cooperating with precise soluble
or membrane-bound receptors [30]. IL-6 has been shown to have a myriad of inflammatory
regulative properties [71], but it can also stimulate acute phase proteins leading to enhanced
vascular permeability, lymphocyte provocation, and antibody creation. IL-6 activation by
nuclear factor kappa B (NF-κB) modulates vascular inflammation [72]. TNF-α is another
proinflammatory cytokine that has been linked to many neurological disorders. Mice
studies have displayed enhanced neuronal loss after lesioning due to the lack of the TNF
receptor compared to normal TNF receptor adequate mice. Additional studies have shown
that TNF-α instigates the presence of protective molecules, such as manganese superoxide
dismutase (MnSOD) [73–75]. New investigations have shown TGF-βs raise APP expression
in cultured astrocytes and microglia and apolipoprotein-E (ApoE) formation in brain slice
culture [30].
Chemokines of the CXC or alpha (α) subfamily consist of positionally conserved
cysteine residues at the amino terminus divided by a single amino acid allowing for chemo-
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taxis of neutrophils and endothelial cells (IL-8). Chemokines direct biological responses via
seven-transmembrane G-protein coupled cell surface receptors (GPCRs). CXC Motif ligand
12 is involved in neurogenesis and mobilizes neurological bodies to sites of lesions in the
CNS [76]. Macrophage migration inhibitory factor (MIF) is a pleiotropic proinflammatory
cytokine that enhances the creation of other inflammatory cytokines and is localized in microglia. Research has demonstrated that MIF attaches to Aβ in AD-compromised areas [76].
Macrophage inflammatory protein 1 (MIP-1α) expression is in numerous neurological and
immunological areas such as astrocytes, microglia, and T cells. Research demonstrated that
the MIP-1α/C-C chemokine receptor type 5 (CCR5) signaling pathway is responsible for
stimulated glial cell aggregation, inflammatory reactions, and synaptic/cognitive dysregulation [76]. Vascular inflammation has been implicated as a progenitor of AD in the form
of rheumatoid arthritis (RH), atherosclerosis, and cardiovascular disease (CVD). Vascular
inflammation may be instrumental in elevating a myriad of proinflammatory mediators
acting via cerebral microvessels such as TNF-α and IL-6 [77].
4.1. Oxidative Stress
Oxidative stress is a condition that is elevated in the brain with aging, produced by an
imbalance in the redox state, involving the generation of excess ROS or the dysfunction
of the antioxidant system. Due to the brain’s excessive metabolic rate and decreased
capacity for cellular regeneration, it is highly susceptible to ROS [78]. The brain also
contains many phospholipids, which are rich in polyunsaturated fatty acids (PUFAs), such
as docosahexaenoic acid (DHA) and arachidonic acid (AA). Research has shown that as free
radical production rises, the PUFA content in the brain gradually decreases [79]. The lipid
hydroperoxides are partially unstable and can automatically degrade into various products,
such as malondialdehyde (MDA), 4-Hydroxynonenal (4-HNE), ketones, epoxides, and
hydrocarbons in the presence of iron. In the AD brain, there is an elevated level of protein
carbonyl. Reactions of various ROS and reactive nitrogen species (RNS) with tyrosine
lead to the production of 3-nitrotyrosine and dityrosine [79]. DNA oxidation can result in
creating 8-Oxo-20 -deoxyguanosine (8-OHdG), which is highly expressed in mitochondrial
DNA of AD patients [79]. In all variations of ROS generation, molecular oxygen must
be triggered, and the cellular system has evolved many metalloenzymes that facilitate
ROS generation upon the interaction of redox metals with O2 utilizing various catalytic
pathways [80].
The mitochondrial electron transport chain expends almost 98% of molecular oxygen
at the cytochrome oxidase complex, and the remaining oxygen is reduced to hydrogen
peroxide and superoxide radicals. During normal metabolism and various functions of
the oxygen radical superoxide anion − (O2 − •) and the non-radical oxidant hydrogen peroxide (H2 O2 ), and hypochlorous acid (HOCl or HClO) are created. When the production
of (O2 − ) and (H2 O2 ) becomes unrestrained, they can result in tissue damage that often
involves the generation of the highly reactive hydroxyl radical (OH·) and other oxidant
molecules in the presence of catalytic iron or copper ions [81]. The brain has abundant
peroxidation-susceptible lipid cells and is an organ with a high indulgence for oxygen.
Moreover, the cerebrospinal fluid cannot bind expelled iron ions. Consequently, oxidative
stress in nervous tissue may seriously damage the brain via several interconnected mechanisms, such as increased intracellular free Ca2+ , the release of excitatory amino acids, and
neurotoxicity [82].
Other progenitors of oxidative stress are RNS, NO, and peroxynitrite (ONOO−), which
can be highly reactive with proteins, lipids, nucleic acid, and other molecules resulting in
modifying the structure and functionalities and having detrimental effects on the brain.
Cells with an accumulation of oxidized products, i.e., aldehydes, protein carbonyls, and
base adducts from DNA oxidation, can be seriously transformed. The large ROS formation
elevated by the electron transport system within the mitochondria under stressful situations
and aging comprises a risk for AD development [81].
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NO not only contributes to oxidative stress but also functions in inflammation [83].
NO is an inflammatory mediator in various joint, gut, and lung diseases, i.e., rheumatoid
arthritis [84]. NO association with the immune system and glial cells has garnered interest in
mediating neurodegenerative diseases, such as AD and PD. Recent research has displayed
NO’s role in vascular dementia [85], in which similar inflammatory molecular mechanisms
can be used in examining AD pathology.
4.2. Nitric Oxide
NO is a multifaceted mediator molecule that is expressed highly in the neurons [86,87].
The enzyme nitric oxide synthase (NOS) was isolated in 1990 in the rat brain (neuronal
nNOS or NOS-1), as well as in macrophages (inducible iNOS or NOS-2) and endothelial
cells (eNOS or N0S-3) [88]. The enzymatic reactions of iNOS are regulated transcriptionally by cytokines, whereas post-translational modifications via Ca2+ /calmodulin control
the activity of eNOS or nNOS [88]. Normally NO is steadily expelled in small increments and functions in vasodilation. Many different immune system cells (leukocytes,
mast cells, platelets, and macrophages) produce and respond to NO [83,86]. NO halts
platelet and leukocyte binding to the endothelium, which diminishes pro-inflammatory
processes [86]. Aging and inflammation increase the generation of the ROS/RNS superoxide anion (O2 − •) that can react with NO to form peroxynitrite (ONOO-), which interferes
with mitochondrial respiration and causes NO dyshomeostasis leading to mitochondrial
dysfunction and neuronal death [88,89]. It has been shown that aging causes decreased
eNOS-generated NO production, leading to increased cardiovascular risks, which can
involve reducing the antioxidant activity, superoxide overproduction, and modifications of
NOS enzyme/expression activity. AD may be correlated with vascular degeneration in the
central nervous acting via NO signaling dysregulation.
Evidence shows that NO-mediated neurotoxicity in AD is caused by microglial cell
stimulation, promoting INOS-regulated NO discharge [89]. Furthermore, pro-inflammatory
cytokine TNF-α induces NO assembly. Immunoreactive components such as macrophages
can produce superoxide through NADPH oxidase [87]. Microglia, glia, and neurons release
high amounts of glutamate [89]. NO can halt respiration and cause glutamate release from
synaptosomes and neurons, hindering mitochondrial respiration and reversing glutamate
uptake or initiating vascular exocytosis [89].
NO has been shown to cause neuronal death via energy depletion-induced necrosis, oxidative phosphorylation, or excitotoxicity [83]. The mechanisms postulated to be involved,
according to the paper by Brown and Bal Price [87], are as follows: (1) stimulation of poly
ADP ribose polymerase (PARP) followed by nicotinamide adenosine diphosphate (NAD+ )
and ATP reduction, (2) promotion of apoptosis by weakly understood reactions, (3) glutamate release, and (4) halting of mitochondrial respiration. Research has shown that cerebral
blood flow diminishes with aging, promoting endothelial cell dysfunction regarding depressed NO discharge [87]. NF-κB is postulated to be involved due to its inflammatory
regulatory properties; eNOS suppresses its activation via proinflammatory cytokines [87].
Microvascolopathy may arise due to the reduced NO release and NF-κB stimulation [87].
NO at reduced concentrations suppresses cytochrome oxidase in contention with oxygen
and may serve as a mediator of cellular energy metabolism [88].
4.3. Autophagy
Autophagy is an evolutionarily preserved mechanism to sustain neuronal homeostasis during cellular development and maturation. It is maintained by lysosomal action,
which controls nutrient recycling in starvation, neurotransmitter release, synaptic restructuring, and pruning during the growth of axons and dendrites [90]. To date, there are
three major types of autophagy in mammals: (1) Macroautophagy, which refers to the
isolation of cytoplasmic materials into double or multi-membrane vesicles called autophagosomes. The process involves developed autophagosomal transport using microtubules
in which cellular byproducts are delivered to degradative compartments; meanwhile,
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during this operation, lysosomes create autolysosomes. (2) Microautophagy involves the
distinct engulfment of the cytosolic substance by invagination of the lysosomal membrane.
(3) Chaperone-mediated autophagy (CMA), which consists of proteins having a pentapeptide pattern (KFERQ-like sequence) that are identified by the cytosolic chaperone heat
shock cognate protein of 70 kDa (hsc70) and its co-chaperones distribute them to the cell
surface of lysosomes [91]. Autophagy plays a pivotal role in cell survival by safeguarding stressful situations, i.e., ER and metabolic stress. Selective autophagy allows better
organelle regulation, limiting the dysfunctional compartment, and pathogen disposal by
uniting the ubiquitin-proteasome system (UPS) and autophagic apparatus. As efficient as
this process may be, conditions caused by overabundance and destabilization can lead to
cell death [92–94].
Aging and inflammation act as precursors to autophagic dysregulation and bolster
cell death by exacerbating the cellular burden misfolded and damaged cellular deposits
and diminishing cellular degradative capacity cells and other modifications of intracellular
proteolytic systems [95]. It has been demonstrated that autophagy modulates critical elements of the immune system, namely, macrophages, lymphocytes, and neutrophils [96].
Autophagic proteins (Beclin1 or ATG16L1) can mediate proinflammatory cytokine production in macrophages and other inflammatory regulators. It can also, in turn, control
cytokine production itself, acting through Il-1β. Countless research in various mammalian
organisms (rodents and humans) has shown that aging contributes to oxidative stress,
DNA damage, and telomere shortening resulting in impaired autophagy, promoting AD
genesis [97,98].
Recent research has shown that in AD, mitophagy (a form of selective autophagy
that involves the mitochondria) dysregulation leads to the aggregation of mitochondrial
debris and destabilization of mitochondrial integrity leading to cell death [93,97]. The
thoroughly researched process of the phosphatase and tensin homolog (PTEN)-induced
the kinase 1 (PINK1)-Parkin pathway depicts the decline of the mitochondrial membrane
potential, which increases PINK1 on the outer membrane of mitochondria (OMM) to
enlist and switch on Parkin, a ubiquitin ligase, via phosphorylation of ubiquitin. Parkin
ubiquitinates numerous OMM proteins, which stimulate the UPS to degenerate these
ubiquitinated OMM proteins, resulting in the mobilization of the autophagy machinery to
instigate the engulfment of impaired mitochondria by phagophore or secluded membranes
and thus create mitophagosomes reserved for removal via the lysosomal system [99].
Evidence of oxidative stress within the AD brain include (1) lipid peroxidation, in which
lipid byproducts, i.e., 4-hydroxy-2,3-nonenal (HNE); (2) protein oxidation in the form of
3-nitrotyrosine and protein carbonyls were observed in the hippocampus of AD patients;
and 3) DNA/RNA damage leads to disrupted DNA repair mechanisms and elevated DNA
mutations exhibited within the hippocampus and cerebral cortex [100].
5. Inflammatory Signaling Pathways Involved in Neurodegeneration
Normal characteristics of aging in the brain are decreased neurogenesis, elevated
synaptic damage, increased metabolic stress, cognitive decline, and immunosenescence.
Aging is also linked to systemic inflammation, increased blood-brain barrier (BBB) permeability, and dysregulated glial cell signaling, influencing chronic inflammation [101]. Normal glial signaling regulating the inflammatory response is the NF-kB, mitogen-activated
protein kinase (MAPK), and phosphoinositide-3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/AKT/mTOR) pathways. The NF-κB pathway has been linked with
inflammation related to aging. NF-κB can be stimulated by ROS, cytokines, inflammatory
agents, growth factors, and synaptic transmission (primarily glutamate). In mice, it was
shown that microglia stimulation induces a highly conserved transcriptional signature
with aging, characterized by NF-κB expression and neuronal death. In rats, elevated NF-κB
expression resulted in the generation of neurodegenerative proinflammatory enzymes:
cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS). Diabetes has displayed an increased risk of AD by 50% by influencing Aβ pathology by NF-κB upregulation
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and independent overexpression of beta-site amyloid precursor protein cleaving enzyme
1 (BACE1). Research on primate and rodent models shows that diabetes and obesity
drive overexpression of NF-κB in the hypothalamus by promoting a feedback loop of
hypertension, overnutrition, and diminished insulin sensitivity [102].
MAPKs consist of serine/threonine kinases triggered via multiple protein kinases
in response to extracellular stimuli by dual phosphorylation at conserved threonine and
tyrosine residues [103,104]. The extracellular signal-regulated kinase (ERK) pathway is a
mediator of neuronal function. ERK1/2 activation occurs by various neurotransmitters
and neuropeptides through induction of ligand-gated ion channels or GPCRS; ERK1/2
primarily regulates cell proliferation and may regulate calcium signaling [103]. The c-Jun
N-terminal kinase (JNK) pathway has been shown to promote neurodegeneration or neuroinflammation via the provocation of potentially deleterious stimuli such as hypoxia,
free radicals, and ROS. The p38 mitogen-activated protein kinase (p38) pathway can be
stimulated by various growth factors (platelet-derived growth factor (PDGF), insulin-like
growth factor (IGF), and vascular endothelial growth factor (VEGF)), pro-inflammatory
cytokines, and oxidative stress resulting in multiple cellular responses such as inflammation, apoptosis, cell growth, and differentiation [103]. IL-6 stimulates Janus kinase (JAK),
which activates signal transducer and activator of transcription (STAT), which provoke the
regulation of inflammatory response.
The phosphoinositide-3-kinase/protein kinase B/mechanistic target of the rapamycin
(PI3K-Akt-mTOR) signaling pathway regulates many cellular metabolism and energy
homeostatic processes, such as proliferation and survival, which can involve the immune
system and CNS. It mediates neuronal physiological conditions, such as learning, memory, and neuroprotection. PI3K is activated by phosphorylation due to the coupling of
various growth factors, such as epidermal growth factor (EGF) and signaling proteins,
i.e., (TLR) ligands bind to receptor tyrosine kinase, which allows for the phosphorylation of
phosphatidylinositol 3,4-bisphosphate (PIP2) to PI (3,4,5)-triphosphate (PIP3) triphosphate,
which stimulates serine-threonine kinase AKT controlled by phosphoinositide-dependent
kinase 1 (PDK1), which can trigger mTOR activation. Current research has shown the
relevance of this pathway to aging and, coupled with AD, can alter normal AKT and
mTOR activity since both are controlled by oxidative stress, decreased nutrient concentration, and innate immune signals. Further, AD upregulates this pathway resulting in
neurodegeneration. The PI3K-AKT-mTOR signaling pathway is linked to insulin regulation
(particularly cerebral insulin), reduced in aging individuals making them more susceptible
to AD [105,106].
6. Contributing Determinants to the Incidence of AD: Health Disparities, Sex,
and Gender
Health inequality involves differences in quality healthcare due to living conditions,
race/ethnicity, socioeconomic status, pollutant exposure, diet, comorbidities, gender, and
family health history [107]. Other noteworthy factors are cognitive reserve, genetic differences in pathological resilience, and educational level. There is a dearth of research
into health inequality effects on minorities, i.e., African Americans (AAs), Latinos, and
Hispanics, related to AD [20,108]. A research article by McDonough [109] introduces the
Weathering hypothesis deduced by Geronimus [110], which states “the cumulative impact
of those mentioned above social, physical, and economic adversities faced by AAs lead to
early health deterioration and advanced biological aging,” which can be used to evaluate
social stressor effects on minority neurological health.
Powell et al. [111] evaluated community effects involved in AD, a cross-sectional investigation of autopsy samples from 447 decedents living in a disadvantaged neighborhood at
the time of death. They found that it was correlated with a heightened risk of Alzheimer’s
disease neuropathology when adjusted for age, sex, and year of death. Another relevant
study was conducted by Saadi et al. [112], who showed that AAs and Hispanics were
less likely (30% to 40%) to see an outpatient neurologist than Caucasians, respectively.
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Furthermore, AAs were prone to being cared for in an emergency room, having frequent
hospital stays, and paying more for inpatient care than Caucasians. Other research has
illustrated how social stressors can exacerbate the risks for AD neuropathy [112,113].
A research area that has not garnered enough attention is the sex and gender differences observed in neurodegenerative disorders. Men and women have different outcomes
concerning a neurodegenerative disease arising from socioeconomic status, level of education, genetics, and hormonal differences [114–116]. Current studies show that sex
differences exist in a cognitive decline concerning AD [117,118]. Bloomberg et al. [119]
evaluated cognitive decline and performance correlated to aging and education and found
that women had stronger memory and lesser memory decline than men regardless of
education level. However, education did play a factor in the fluency tests, in which women
that were higher educated and in the later cohort had higher scores than the men. Still,
there were no sex differences in fluency decline [119].
Androgens (testosterone) and estrogens may serve to prevent and treat neurodegenerative diseases due to their many anti-inflammatory properties, such as halting proinflammatory cytokine production, protection from oxidative stress, and modulation of Aβ
production [120,121]. Several investigations show that estrogen’s neurological roles in
regulating the effects of the trophic factors in the brain heighten the cerebral blood flow,
restrain atrophy of cholinergic neurons, and adjust BBB glucose transporter expression
and membrane translocation [122,123]. Aging is liable to cause a loss of sex hormones
(androgens and estrogens), which induce muscle loss, muscle weakness, diminished functional performance, and reduced life span [124,125]. Postmenopausal women (age 65 and
over) are more susceptible to AD than men [122]. Immunological sex differences exist in
microglia, as shown in microglial transcriptomic and proteomic studies that change with
age [126,127].
7. Preventive Measures for Neurodegenerative Disease: Nutraceutical and
Phytochemical Use in Neurodegenerative Disease
Regarding AD, there have been no new FDA-approved drugs since 2003 and no authorized disease-modified treatment (DMT), although there have been many extensive clinical
trials [32,33,128]. Considering this fact, the advent of nutraceuticals has led to a possible
new form of control of this disease. Nutraceuticals are a broadly defined term that comprises many products that arise from the food industry, herbal and dietary supplement
trade, pharmaceutical, and hybrid agribusiness/nutrition enterprises that may have potential medicinal value in treating disease [96]. Nutraceuticals have gained tremendous interest
due to their long history of use and providing a natural alternative to the current pharmaceutical drugs in the market [96]. Nutraceuticals have been shown to have anti-inflammatory,
antioxidative, and anti-aging properties. The anti-inflammatory/antioxidative processes
carried out by nutraceuticals are as follows: (a) hinder NFκB activation, (b) inhibiting
overexpression of proinflammatory cytokines, (c) downregulation of the overexpression of
calcium/calmodulin (CAM) and enzymes, (d) block enzymatic action of COX-2 and iNOS,
(e) arrest ROS enzymatic production, and (f) elevate ROS scavenging [129].
Phytochemicals are nutraceutical plant chemicals with either defensive or disease
protective roles [130]. Some common phytochemicals are green tea polyphenols, phytoestrogens, anthocyanidins, carotenoids, and terpenoids. Phytochemicals have been shown to
have many antioxidative and anti-inflammatory properties, as evidenced using berberine,
which has been found to stimulate the phosphoinositide-3-kinase/protein kinase B/ nuclear
factor erythroid 2 related factors 2 (PI3K/Akt/nrf2) pathway to negate ROS generation.
The use of phytochemicals in autophagy has been displayed in cancer research. As stated
previously, autophagy is a catabolic process in which damaged or impaired molecules and
organelles are degraded by lysosomes for removal from the body.
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One example of a phytochemical is quercetin (3,30 ,40 ,5,7-pentahydroxyflavone), which
resides in many fruits and vegetables, such as apples and berries, and onions have shown
autophagic induction in Schwann cells by alleviating the cell damage generated by elevated
glucose [131]. It also diminishes lipopolysaccharide (LPS)-induced nitric oxide release from
a mouse neuroglia cell line [131]. Further anti-inflammatory actions were found in luteolin
(5,7,30 ,40 -tetrahyderoxyflavone), which is found in celery, parsley, green pepper, chamomile
tea, and perilla leaf, and decreases iNOS and COX-2, and thus downregulates inflammatory
mediators, formation of NO, and prostaglandin E2 in LPS-activated BV2 microglial cells.
It also enhanced neuron viability and decreased apoptosis in rat primary hippocampal
neurons stimulated with lipopolysaccharide (LPS) administered at 20 mM [132].
Green Tea and Its Derivatives: Therapeutic Actions Related to Inflammation
and Neurodegeneration
Tea is the second most frequently drank beverage in the world after water [133,134].
Tea has been consumed both socially and habitually since 3000 B.C. Camellia sinensis (L.)
(C. Sinensis L.), which is a member of the Theaceae family (evergreen plants), is a resident
of China that later spread to India, Japan, Europe, Russia, and the New World (Americas)
in the 17th century. Green, Oolong, and black tea all originate from the same plant species,
C. Sinensis L, but are dissimilar in appearance, organoleptic taste, chemical content, and
flavor [135]. The chemical constituents of green tea leaves consist of polyphenols (catechins
and flavonoids), alkaloids (caffeine, theobromine, and theophylline), volatile oils, polysaccharides, amino acids, lipids, vitamins, inorganic components, aluminum, fluorine, and
manganese). Green tea consists of six main catechin compounds, catechin, gallocatechin,
epicatechin (EC), epigallocatechin (EGC), epicatechin gallate (ECG), and EGCG, which is
the most active component. Two derivatives that are being researched thoroughly are gallic
acid (3,4,5-trihydroxybenzoic acid) and (−) epicatechin gallate (EC).
GA is a plentiful phenolic compound found throughout the plant kingdom. It furnishes and improves the anti-inflammatory, antioxidative, and neuroprotective attributes
of EGCG [136,137]. An analysis performed by Mori et al. [138] revealed that GA administration rescinded impaired learning and memory in a mutant human amyloid β-protein
precursor/presenilin 1 (APP/PS1) transgenic AD mouse model. It also reduced cerebral
amyloidosis and increased nonamyloidogenic APP processing. Brain inflammation, gliosis,
and oxidative stress were quelled. GA was able to raise α and β secretase response, impede neuroinflammation, and balance brain oxidative stress in a pre-clinical mouse AD
model [138]. Moreover, in the same study, GA displayed the ability to elevate disintegrin
and metalloproteinase domain-containing protein 10 (ADAM10), proprotein convertase
furin, and initiate ADAM10, which inhibits BACE1 activity. In an investigation by Andrade et al. [139], GA exhibited anti-amyloidogenic properties (in which in vitro neuronal
membranes), which modulate the GA-induced Aβ fibril disaggregation, that could be
associated with the moderate affinity of the compound for the lipid membrane. GA can
cooperate with α-synuclein to halt amyloid fibrillogenesis in PD progression [140–142].
Liu et al. [143] demonstrated that GA diminished LPS-induced elevation in heme
oxygenase-1 level (a redox-regulated protein) and α-synuclein accumulation, proposing
that GA is capable of inhibiting LPS-induced oxidative stress and protein conjugation. In
addition, GA hinders LPS-induced caspase 3 activations (a biomarker of programmed
cell death), and LPS stimulates increases in receptor-interacting protein kinase (RIPK)1 and RIPK-3 levels (biomarkers of necroptosis). This suggests that GA inhibits LPSinduced apoptosis and necroptosis in the nigrostriatal dopaminergic system of rat brain
co-incubation of GA attenuating LPS-induced increases in iNOS mRNA and iNOS protein
expression in the treated BV-2 cells, as well as NO production in the culture medium. Most
importantly, GA protects against mitochondrial dysfunction, DNA damage, and apoptosis
that occurs in AD, as evidenced in a rat model in which it altered a multitude of antioxidant
enzymes such as SOD, glutathione peroxidase (GPx), catalase, glutathione-s-transferase
(GST), and glutathione (GSH) content [137]. GA provides antioxidative protection against
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a chemically induced hypoxia/reoxygenation model of cerebral damage by inhibiting the
mitochondrial ROS accumulation and simultaneously increasing oxidative phosphorylation
and ATP synthesis [137].
EC is a green tea derivative, but it can also be found in berries, apples, grapes, peanuts,
and cocoa tea. EC has the general chemical structure of other flavonoids of the C6-C3C6 configuration. It consists of two aromatic rings linked by a heterocycle formed by
an additional three-carbon chain and one oxygen atom. Current research is focused on
metabolic stress disorders that are associated with neurodegenerative disease development.
One, in particular, is obesity, which is caused by a consistent imbalance of energy intake
and expenditure characterized as abnormal or excessive fat build up that disrupts the
normal adipose tissue surveillance and energy regulation. This leads to adipose tissue
inflammation, which can lead to system-wide comorbidities, such as insulin resistance,
T2D, cardiometabolic disorders, and advances the aging process, resulting in heightened
risk for age-related diseases, i.e., AD and PD [144,145]. EC can quell GI inflammation via its
antioxidant properties (decrease NADPH upregulation and heightened oxidant production)
and anti-inflammatory functions by reducing the stimulation of inflammatory signaling
(ERK1/2 and NF-κB) [146]. EC demonstrated the ability to mediate lipid regulation as
exhibited in dyslipidemias, which enhances the risk of atherosclerosis [146]. EC has
been shown to alleviate insulin resistance in in vivo animal studies by reducing glucose
and insulin levels, refining insulin sensitivity, and improving glucose metabolism [146].
Finally, EC has been shown to improve cognitive impairment, but also to elevate brainderived neurotrophic factor (BDNF), which is a neurotropin involved in learning and
memory. EC may have neuroprotective abilities by enhancing cerebral blood flow and
attenuating endotoxin-mediated inflammation caused by inflammatory mediator aberrant
transport [146].
8. EGCG Synthesis, Structure, and Therapeutic Action
EGCG is an ortho-benzoyl benzopyran byproduct [147], comprised of four rings
marked A, B, C, and D (Figure 2). A and C embody the benzopyran ring, which has a
phenyl group at C2 and a gallate group at C3. The B ring has positional 3,4,5-trihydroxyl
groups, and the D ring galloyl moiety is configured as an ester at C3. The medicinal
properties of green tea are due to EGC esterification with gallic acid (galloylation), allowing
for the antioxidative mechanisms of green tea correlated to EGCG [148].
Green tea polyphenol acting by way of EGCG’s unique structure allows for highly
efficient antioxidative properties. EGCG counteracted superoxide anion and hydrogen
peroxide and blocked ROS-induced DNA damage. EGCG is a peroxynitrite scavenger
reducing the nitration of tyrosine and a forager of free radical byproducts, such as hypochlorite and peroxyl radicals. It can also act as a chelator of iron and other metals via its phenolic
groups, allowing binding to inactive forms of Fe(III), Cu, Cd, and Pb, leading to reduced
amounts of free forms of these metals, thus promoting ROS reactions [149]. In addition,
green tea polyphenol antioxidative functions are displayed by enhancing the activity of
glutathione peroxidase (GPX) and superoxide dismutase (SOD), and the scavenging rate is
much stronger than vitamins C and E [150].
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materials, i.e., lipids, proteins, and carbohydrates as carriers. One example is the study by
carbohydrates as carriers. One example is the study by Liu et al. [154] in which a palmiLiu et al. [154] in which a palmitate version of EGCG was isolated and determined as 40tate version of EGCG was isolated and determined as 40-0-palmitoyl EGCG. It had better
0-palmitoyl EGCG. It had better stability and durability to digestive enzymes (α-amylase).
stability and durability to digestive enzymes (α-amylase). Current studies show the lipid
nano-carriers to be the most effective over the other nanoparticles due to their high stability
and biocompatibility, controlled release properties, low-cost production methods, and easy
scalability [155,156].
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phenols have exhibited many disease-alleviating properties, specifically EGCG, which has
shown many medicinal attributes, particularly neuroprotective (as evidenced in Figure 3).
Animal research has shown that EGCG has anti-aging abilities due to its capability to act
as a free radical scavenger [160]. EGCG has been shown to affect many potential targets
related to AD. It can protect against beta-amyloid-induced neurotoxicity in cultured hip16 of 34
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In PD, EGCG’s medicinal properties have been exhibited in its neuro preventative
abilities, as evidenced in an in vitro study in rotenone (a pesticide that induces Parkinson’s
symptoms similar to humans) in rats. This investigation showed that EGCG reduced the
measurable molecular impairments of PD, such as lipid peroxidation, oxidative stress
(NO biomarker), and other neuroinflammatory and apoptotic markers for PD [162]. Tau
phosphorylation may be prevented by EGCG [163] via ionic bond strength [164]. A solutions’ ionic strength (through NaCl) can modify the rate of aggregation via changing
the electrostatic attractions between protein molecules. This can alter the conformation
and morphology of the fibrils that coalesce during aggregation [164]. In another study, it
was shown that EGCG could stop human tau phosphorylation and interact with tau using
various biochemical and bioanalytical experiments, such as isothermal titration calorimetry
and thioflavin S (ThS) fluorescence assay [165].
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10. Autophagic Role of EGCG
Several research investigations are examining the mechanisms of EGCG mediation
of autophagy using various in vitro disease cell model systems. Kim et al. [166] showed
that EGCG, at a low concentration of 10 µM, could induce autophagy and autophagic
flux in endothelial cells that aid in the degeneration of lipid droplets via the calcium
(Ca2+ )/calmodulin-dependent protein kinase β (CaMKKβ)/50 AMP-activated protein kinase
Biomolecules 2022,
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system explored
extensively in cancer research. The promotion of molecular insults, i.e., ER stress,
hypoxia, and chemotherapy, initiate the AMPK or MAPK/AKT/mTOR pathway, which recruits
downstream effector protein kinases Unc-51 like autophagy activating kinase (ULK1/2,) and RP200
leading to the cascade of events leading to degradation of cellular debris. EGCG can act via AMPK
or MTORC1 and act indirectly on autophagic-like proteins (ATG9) and ATG-9-15 to induce the
autophagic series of events resulting in cellular debris breakdown and leading to the residue being
reused for proper cellular growth and homeostasis.
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11. Other EGCG Therapeutic Applications for Neuroinflammation and Neurorescue in
Other Related Pathological Disorders
EGCG’s medicinal characteristics have been explored in multiple cells and animal
models involving inflammation, immunomodulatory, and ROS regulation, especially in the
contemporary literature [170]. As discussed previously, in the medicinal properties of green
tea, the focus has been on the link between the inflammatory effects on the cardiovascular
system and its correlation with neurodegenerative diseases. This is evidenced in cigarette
smoking, which heightens ROS production and contributes to the upsurge of inflammatory
response seen in coronary heart disease and stroke [171]. EGCG displayed the ability to
diminish cigarette smoke-stimulated inflammation in human cardiomyocytes utilizing the
MAPK and NF-κB signaling routes. Airway inflammation is exhibited in bronchial asthma,
a chronic respiratory disorder that is increasing globally due to air pollution and other
environmental changes [171]. It was shown that EGCG elevated IL-10, CD4+ , CD25+ , and
Foxp3+ Treg cells and expression of Foxp3 mRNA in lung tissue, which all contributed
to a reduction in airway inflammation in the female BALB/c mice model [171,172]. T cell
dysregulation exacerbates atherosclerosis advancement, which is correlated to congenital
heart disease. The integration of T cells into atherosclerotic lesions expel pro-inflammatory
cytokines, which promote the expression of MHCII complex antigens on macrophages and
vascular smooth muscles. EGCG can halt this proinflammatory expression, thus negating T
cell dysregulation [173].
Another example of immunomodulation by EGCG is on the receptor activator of
NF-κB (RANKL), which is expressed in osteoblasts, epithelial cells, and initiated T cells.
EGCG inhibited caspase-1 activity and reduced transcriptional activity of nuclear factor
(NF)-κB by halting inhibitory protein κBα phosphorylation in RANKL-stimulated HMC-1
cells [174]. Moreover, rheumatoid arthritis, a chronic age-related inflammatory disorder,
was shown to be elevated by ROS generation, but EGCG has exhibited ROS reductive
capabilities in a Wistar mouse model to balance the oxidative-antioxidative system [175].
Lastly, metal toxicity (such as Pb3+ and Cd2+ ) contributes to and worsens inflammation and
normal energy homeostasis in the cerebro-cardiovascular and other related systems [149].
EGCG has been shown to reduce this toxicity via its antioxidative properties [176–179].
The brain vasculature, which consists of a complex distribution of arteries, veins,
and capillaries, circulates essential substances like oxygen and glucose to the brain while
eliminating waste products such as CO2 [63]. Proper blood flow is important for optimal
brain function [63]. Various research has been focused on the antioxidative properties for
the treatment of coronary artery disease, which is correlated with high oxidative stress and
dysfunction of the endothelium. Green tea does not reduce blood pressure or plasma lipids,
but does inhibit lipid peroxidation, reduce cholesterol levels (in mice), and minimize the
development of aortic atherosclerosis in rabbits [160].
Several investigations have shown that cardiovascular dysfunction (hypertension,
diabetes, atherosclerosis, and ApoE allele ε4) is linked to AD [180–182]. AD-like amyloidbeta deposits have been observed in the neutrophil and within neurons of non-demented
patients with heart disease [180–182]. Vascular tissue dysfunctions found in patients
with AD involve diminished microvascular density, blood vessel fragmentation, atrophy,
elevated capillary irregularity, alterations in blood vessel diameter, increased thickness
of basement membrane, and collagen accumulation in the basement membrane [180]. It
has been postulated that a defective cerebrovascular system could halt the removal of
Aβ, resulting in increased concentration in the brain. Furthermore, BBB disruption may
allow for plasma proteins and fibrinogen to enter the brain parenchyma, which can induce
inflammation and instigate neurodegeneration [183].
Aging alters the integrity of the brain and cognitive ability by intensifying the biomechanical force of the cerebral vasculature and changing vascular remodeling [184]. Chronic
inflammation is an inducer of atherosclerosis by stimulating the vascular endothelium,
elevating the adhesion of mononuclear cells to the incapacitated endothelial layer, and
extravasation into the vessel wall. Green tea polyphenols may alleviate vascular endothelial
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dysfunction and inflammation by upregulating eNOS levels, elevating VEGF expression,
and halting endoplasmic reticulum/oxidative stress. The green tea polyphenol EGCG
was observed to constrain angiotensin II and TNF-α-induced hypertrophy by inhibiting
ROS-promoted stress in cardiomyocytes [185]. Epidemiological studies have shown that
green tea consumption causes a 5-10-fold lower incidence of PD in Asian populations [160].
The interconnectedness between the immune, cardiovascular, and nervous systems are
linked to endothelial dysfunction and inflammation, which are factors involved in the
pathogenesis of AD that may be alleviated by the medicinal actions of EGCG.
Role of microRNA (miRNA) in AD: Medicinal Action by EGCG
MicroRNAs (miRNA) are non-coding single-stranded RNAs (usually 22–23 nucleotides
in length) that regulate gene expression on the 30 untranslated region (UTR) of messenger RNA (mRNA) by halting translation or initiating degradation of the marked
mRNA [186,187]. miRNAs reside in the nervous system, where they control advanced
neuronal processes such as synaptic plasticity. MicroRNAs (miRNAs) can modulate
the innate and adaptive immune responses, mainly miR-21, miR-155, miR-125b, and
miR-146a, which are drastically up-regulated in neurodegenerative diseases [188]. miR155
is an established pro-inflammatory miRNA for the innate immune response; resveratrol
(3,40 ,5-trihydroxy-trans-stilbene) can debilitate the up-regulation of this miRNA by LPS in a
miR-663 dependent approach [188]. In AD, miRNAs have displayed the ability to direct the
activity of APP and BACE1, thus suppressing the production of Aβ as evidenced, presently,
in mIR-132 [189,190].
Current research has shown that miRNAs may be able to stimulate TLRs and mediate
neuroinflammatory processes by acting on inflammatory cytokines (examples are mIR-9
and mIR 155), which suppress inflammation by regulating downstream proinflammatory
activators such as TNF receptor-associated factor 6 (TRAF6). miRNAs may also serve
as effective biomarkers due to their appearance in serum, plasma, or cerebrospinal fluid,
allowing for degradative protection and stability from environmental insults, as well as
their ability to be easily gathered and analyzed via current technology, i.e., next-generation
sequencing (NGS) [189]. In terms of EGCG effects on miRNA in neurodegenerative disease,
in particular, AD, there is a dearth of knowledge, although the anti-inflammatory effects
of EGCG have been shown to increase miRNA expression in chondrocytes and reduce
inflammation in osteoarthritis by acting on miR-199a-3p by reducing the stimulation of
COX2. The production of prostaglandin E2 (PGE2), as well as interleukin 1, will be inhibited, and its effects on the enzyme ADAM metalloproteinase with thrombospondin type
1 motif (ADAMTSS) [191,192]. Furthermore, EGCG was shown to reduce the prevalence
of miRNA in the serum of an APP/PS1 transgenic mouse [193]. Based on this, EGCG
may act indirectly on miRNA to reduce age-related neuroinflammation and act as a neuroprotective measure in AD pathology. Although miRNA treatment exhibits promising
and innovative approaches to alleviating AD, it also has its shortcomings, such as the
association between miRNA and the gene of interest not always being 1:1, which makes
gene targeting difficult. Next, natural variations in miRNA expression patterns are to be
pondered during experimental design. Single-stranded miRNA show decay kinetics in
particular circumstances. Lastly, data interpretation of miRNA expression depends on the
detection platform used [187].
12. EGCG in Clinical Studies of AD and PD
Most of the examination of the medicinal benefits of EGCG in neurological disease has
been performed in vitro and in vivo, as displayed in Table 1. The clinical trials pertaining
to EGCG, AD, and PD were acquired from ClinicalTrials.gov and are shown in Table 2.
A total of 3 studies were taken from this site, in which two were completed and only one
is ongoing. A detailed description is shown in Table 1. In the first study (NCT00951834),
participants were elderly adults (aged 60 and over). The inquiry aimed to evaluate EGCG’s
anti-protein aggregation properties in AD by preventing the induction of alpha-secretase

Biomolecules 2022, 12, 371

20 of 34

and the endothelin-converting enzyme, as well as to prevent the aggregation of betaamyloid to toxic oligomers through the direct binding to the unfolded peptide. There were
no results mentioned for this investigation. The next examination (NCT03978052) was
recruiting elderly adults and focused on the premise that many adjustable risk factors for
AD have been identified in observational studies, which are radical and do not apply any
effects through amyloid or tau. This implies that primary prevention studies focusing
on risk reduction and lifestyle modification may offer further benefits. The last analysis
(NCT00461942) was to ascertain whether EGCG/ECG is effective and safe in the treatment
of de novo Parkinson’s disease. This study observed 30-year-old adults, and the results
were not mentioned. Unfortunately, due to its poor bioavailability and inconclusive evidence as an effective monotherapy, there is a dearth of clinical data related to autophagy,
neuroinflammation, and senescence related to EGCG and AD. Ongoing investigation coupling EGCG with other agents may show promise [194]. As mentioned previously, various
pharmaceutical modifications to improve the effectiveness of EGCG are ongoing. The
proposal of a new model system to investigate autophagy in neurodegenerative disease
may show promise, as discussed by Tzou et al. [195] in the use of drosophila.
Table 1. Possible mechanisms of EGCG neuroprotective action in AD demonstrated in various
disease models.
Pharmacological Action

Model (In Vivo/In Vitro)

Therapeutic Focus

Reference

In vivo
transgenic mice, human volunteers,
Elegans, hamsters, Drosophila

A review of the role of green tea
(Camellia sinensis) in antiphotoaging,
stress resistance, neuroprotection,
and autophagy

[161]

In vitro and in vivo
airway epithelial cells, experimental
autoimmune encephalomyelitis
(EAE), rat aortas, RA human patients,
human umbilical vein endothelial
cells, and synovial fibroblasts

The prevention and treatment of
vascular inflammation in rheumatoid
arthritis

[185]

In vivo:
human

Molecular pharmacology of
inflammation: medicinal plants as
anti-inflammatory agents

[170]

In vitro:
adult human ventricular
cardiomyocyte cell line AC16

Suppresses cigarette
smoking-induced inflammation in
human cardiomyocytes, utilizing
ROS-mediated MAPK and NF-κB
pathways

[171]

In vivo:
Wistar albino female rats

Attenuates arthritis by regulating
Nrf2, HO-1, and cytokine levels in an
experimental arthritis model

[175]

In vivo:
Human mast cell line

Blockade of RANKL/RANK
signaling pathway by EGCG
alleviates mast cell-mediated
inflammatory reactions

[174]

Anti-inflammatory
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Table 1. Cont.
Pharmacological Action

Antioxidant/oxidative
stress

Amyloid-beta
formation inhibition

Model (In Vivo/In Vitro)

Therapeutic Focus

Reference

In vitro:
human bronchial epithelial cells

Diminishes cigarette smoke-induced
oxidative stress, lipid peroxidation, and
inflammation in human bronchial
epithelial cells

[172]

In vitro:
Single ventricular myocytes

Protective effects against lead-induced
oxidative damage

[177]

In vivo:
Adult male Wistar albino rats

Attenuates
cadmium-induced chronic renal injury
and fibrosis

[179]

multiple human and cell model systems

EGCG Management of Heavy
Metal-Induced Oxidative Stress:
Mechanisms of Action, Efficacy, and
Concerns

[149]

In vitro
BEAS-2B cells and EBV-BL cells

Protects against chromate-induced
toxicity in vitro

[178]

In vivo
Male 14-day-old Wistar rats

Protects rat brain mitochondria against
cadmium-induced damage

[176]

In vivo
human adult brain

Microglial dysfunction in brain aging
and Alzheimer’s disease

[65]

In vitro
N2a-APP695 cells

EGCG attenuates β-amyloid generation
and oxidative stress involvement of
PPARγ

[196]

In vitro and in vivo
Human embryonic kidney cells human
CNS-derived neuroblastoma cells,
APPHEK293 and SwAPP-N2a cells.
Biomarkers of CSF, plasma, blood-derived
brain exosomes, monocytes, and peripheral
blood mononuclear cells

Autophagy modulation as a treatment
of amyloid diseases

[197]

In vitro
hippocampal neurons, mouse, rat brain
cells, and yeast model overexpressing htt

EGCG Amyloid Aggregation and
Neurodegenerative Diseases

[158]

In vivo
mixed POPC/POPG (7:3) lipid bilayer

Plays a dual role in Aβ 42 protofibril
disruption and membrane protection:
A dynamic molecular study

[198]

In vitro
Synthetic Aβ42, Aβ fibril formulation

The effect of
(−)-epigallocatechin-3-gallate on the
amyloid-β secondary structure

[199]

In vitro
C3H10T1/2 cells and 3T3-L1 preadipocytes

Effects of EGCG on autophagic
lipolysis in adipocytes

[166]

In vitro
HEPG2 cells

A new molecular mechanism
underlying the EGCG mediated
autophagic modulation of AFP

[147]

Human endothelial cells

Protects vascular endothelial cells from
oxidative stress induced damage by
targeting the autophagy dependent
PI3K-Akt-mTOR pathway

[167]

HEK293T cells

Promotes autophagy dependent
survival via influencing the balance of
mTOR -AMPK pathways upon
endoplasmic reticulum stress

[168]

Autophagy
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Table 1. Cont.
Pharmacological Action

Cholesterol/Lipid
Metabolism

Model (In Vivo/In Vitro)

Therapeutic Focus

Reference

high-fat diet induced mouse obesity
model, human volunteers, rats,

The beneficial effects of principal
polyphenols from green tea, coffee, wine,
and curry on obesity

[37]

BV2 cells and Twenty-four-week-old
male C57BL/6J mice

Attenuates neuroinflammation in palmitic
acid-stimulated bv-2 microglia and high-fat
diet-induced obese mice

[200]

C57BL/6 mice

prevents inflammation and diabetes
-induced glucose tolerance through
inhibition of NLRP3 inflammasome
activation

[201]

broiler chickens

Effects of EGCG on lipid metabolism and
its underlying molecular mechanism

[202]

SH-SY5Y cells, SAMP10, and ddy mice

A review of the role of green tea (Camellia
sinensis) in antiphotoaging, stress
resistance, neuroprotection, and autophagy

[161]

36 weeks old, spontaneously
hypertensive rats and male
normotensive Wistar-Kyoto rats

Green tea suppresses brain aging

[203]

3T3-L1 preadipocytes

Cerebral cortex apoptosis in early aged
hypertension: effects of
epigallocatechin-3-gallate

[204]

Wistar albino rats

Suppresses premature senescence of
preadipocytes by inhibition of
PI3K/Akt/mTOR pathway and induces
senescent cell death by regulation of
Bax/Bcl-2 pathway

[205]

APP/PS1 transgenic mouse model

Identification of circulating mir-125b as a
potential biomarker of Alzheimer’s disease

[193]

chondrocytes, human THP-1 monocytic
cells, and primary human fibroblasts

Quercetin, epigallocatechin gallate,
curcumin, and resveratrol: from dietary
sources to human microrna modulation

[192]

Sprague Dawley Rats, chondrocytes,
monocytes, and mice

Targeting miRNAs by polyphenols: a novel
therapeutic strategy for aging

[191]

Anti-Aging

MicroRNA

Table 2. Current clinical studies of EGCG on AD and PD.

Study
Identifier

Study
Type

NCT03978052 Interventional

Study
Population

Study Purpose

Study
Participants

Spain

Prevention of
cognitive decline in
ApoE4 carriers with
subjective cognitive
decline after EGCG
and a multimodal
intervention

Alzheimer’s
Disease
cognitive
function
nutritional
intervention

Number
of
Patients
Recruited

Intervention

Status

200

Dietary Supplement:
EGCG, Placebo
EGCG, personalized
intervention, and
lifestyle
recommendations

Recruiting
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Table 2. Cont.

Study
Identifier

Study
Type

Study
Population

NCT00951834 Interventional Germany

NCT00461942 Interventional

China

Number
of
Patients
Recruited

Intervention

Status

Completed

Completed

Study Purpose

Study
Participants

Sunphenon EGCg
(EpigallocatechinGallate) in the early
stage of Alzheimer’s
disease

Alzheimer’s
Disease

21

Drug:
EpigallocatechinGallate Drug
Placebo

Efficacy and safety
of green tea
polyphenol in de
novo Parkinson’s
disease patients

Parkinson’s
Disease

480

Drug: Green Tea
Polyphenols
(EGCG/ECG)

13. Lipids, Cholesterol Metabolism, and AD: A New Possibility for EGCG?
Lipids have a multitude of functions, i.e., cellular metabolism, structural integrity, and
energy modulation. Aging, unregulated food consumption, and reduced physical activity
have led to a worldwide epidemic of obesity, insulin resistance, and metabolic conditions
leading to diabetes, hyperlipidemia, and hypertension [206,207]. Body fat composition
increases with age and is stored primarily in the abdominal region, elevating the susceptibility to cardiovascular disease and diabetes in the elderly [208]. Aging is also linked with
a reduction in fat oxidation, which results in fat accumulation. Fat oxidation involves the
release of fatty acids from adipose tissue and the aptitude of respiring tissues to oxidize
fatty acids. Lipids serve as progenitors for many secondary messengers, i.e., arachidonic
acid (AA), docosahexaenoic acid (DHA), and 1,2-diacylglycerol (DAG) [209]. The brain
lipid composition comprises sphingolipids, glycerophospholipids, cholesterol ester, and
fragments of triglycerides.
Cholesterol is a significant portion of the brain (the brain is a majority cholesterol-rich
organ) due to its role as a necessary constituent of cell membranes [210]. It serves as
the progenitor of steroid hormones, bile acids, fats, and lipophilic vitamins. Cholesterol
mediates proper synaptic plasticity, axonal direction, and synaptic development [211].
It also regulates many physiological brain functions, primarily through its concentration in
lipid rafts. Cholesterol also mediates apoptosis (mitochondrial cholesterol) and clearance
mechanisms (lysosomal cholesterol) [212]. Cholesterol can be acquired through the diet
or endogenous synthesis; therefore, cholesterol homeostasis relies on the regulation of
lipoprotein trafficking. Modifying cholesterol metabolism by aging may heighten the risk
for metabolic and cardiovascular diseases and neurodegenerative diseases, such as AD.
The BBB serves to halt the uptake of lipoproteins from circulation and regulate its clearance
via the conversion of cholesterol to its metabolite—24-hydroxycholesterol [150,213].
Cholesterol biosynthesis is a multivarious process involving converting acetyl coenzyme A (Acetyl CoA) to 3-hydroxy-30 methylglutaryl-CoA by hydroxymethylglutarylCoA (HMG-CoA) synthase, which is changed to mevalonate by HMG-CoA reductase.
A sequence of enzymatic reactions converts mevalonate into 3-isoprenyl pyrophosphate,
farnesyl pyrophosphate, squalene, lanosterol, and via a 19-step process to cholesterol [214].
Cholesterol biosynthesis dysregulation has effects on the two significant age and inflammatory intracellular pathways mechanistic target of rapamycin (mTOR) and the NAD+ dependent deacetylase silent information regulator proteins (sirtuins) [215].
Statins are drugs that halt cholesterol biotransformation through the competitive inhibition of 3-hydroxy-3-methylglutaryl co-enzyme A reductase (HMGCR), thus preventing
the conversion of HMG-CoA into mevalonate [216]. Scientific investigation has shown
that statins can also provide neuroprotection by modulating nitric oxide production and
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that statins can also provide neuroprotection by modulating nitric oxide production and
eNOS, enabling a reduction in ischemic stroke and reducing the ROS involved in this condition [216]. Furthermore, statins contribute to neurorescue and utilize cholesterol-dependent mechanisms by decreasing interferon-stimulated expression of MHC-II on antigen-presenting cells (APC) [216]. Serum cholesterol levels are instrumental in Aβ promotion in AD, so its mediation by a potential HMGR inhibitor deserves further research and 24 of 34
evaluation. A contemporary study demonstrated that statins could alleviate the cognitive
deficiency of Sprague-Dawley male rats with experimental AD, lessen the stimulation of
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3-hydroxy-3-methylglutaryl-CoA by hydroxymethylglutaryl-CoA (HMG-CoA) synthase, which is
changed to mevalonate by HMG-CoA reductase. A succession of enzymatic reactions converts mevalonate into 3-isoprenyl pyrophosphate, farnesyl pyrophosphate, squalene, lanosterol, and cholesterol
leading to the generation of the oxysterol 27-hydroxycholesterol due to the enzymatic action of
cholesterol 24S-hydroxylase (CYP46). The high amounts of oxysterols, i.e., 27 hydroxycholesterols
(27-OHC the role), can contribute to AD biogenesis. (B) EGCG acting similar to a statin may be able
to negate this elevation by inhibiting the regulative enzyme HMG-COA reductase, which will reduce
the production of the oxysterols by preventing the enzymatic conversion of mevalonate resulting in
the prevention of AD.

In the liver, insulin resistance enhances hepatic glucose production and lipogenesis,
advancing to hyperglycemia and lipotoxicity-induced pancreatic β-cell dysfunction. The
liver also serves as a clearance mechanism in the brain [221]. Zhou et al. [222] displayed
how EGCG elevated hepatic autophagy by inducing the generation of autophagosomes,
enhanced lysosomal acidification, and triggered autophagic flux in hepatic cells and in vivo
as well as lipid clearance. EGCG’s antioxidant, fatty acid, and cholesterol metabolism
effects reduced glucolipid metabolism and oxidative stress in type 2 diabetic rats [223].
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EGCG was shown to act on the 50 AMP-activated protein kinase (AMPK) phosphorylation
and modify gut microbiota [224]. Lastly, EGCG regulated the lipid metabolism in the
acclaimed poultry model for obesity: the boiler chicken [202].
14. Future Directions
AD is on pace to be the fastest-growing worldwide epidemic in the next few years [225].
Current research on AD should be focused on advancing our understanding of phytochemical intervention in inflammaging, cholesterol metabolism, microglia-neuronal interactions,
epigenetics, neuroprotection, and autophagy to create a more robust alternative therapy to
combat AD. The enhancement of EGCG bioavailability and combination immunotherapies
may be of scientific interest. Research focused on BBB barrier dysfunction and mitochondrial disruption by environmental toxicants on in vitro models and the administration of
green tea catechins such as EC and EGCG. Scientific analysis on health disparities and
comorbidities, especially in association with metabolic stress, may be of concern. This
review also highlights the need for in vitro studies on green tea catechins (EGCG/EC)
coupled with physical activity and calorie restriction in preventing neurodegenerative
disease. Lastly, researchers should evaluate preventive measures by green tea catechins on
protein aggregation/misfolding and neuroinflammation in concussion and reduction of
susceptibility to neurodegenerative pathogenesis.
15. Conclusions
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This review showcased the therapeutic actions of polyphenols and introduced the
medical benefits of green tea catechins. The ameliorative and neuroprotective properties of
EGCG were discussed in relation to neuroinflammation, aging, protein aggregation, and
autophagy (Figure 6). EGCG was shown to quell neuroinflammation by reducing microglial
activation. Aging was discussed as the main factor of heightening neurodegenerative
disease development. This was discussed in association with the immunosenescence of
microglia. AD and PD were used as the main archetypes of neurodegenerative pathology,
and both are rising in significance as global aging populations increase. The protein tau
was introduced and discussed for its role in understanding pathological fibrillogenesis.
Autophagy, a common research interest in cancer, has gained interest in neurodegenerative
disease to understand the dysregulated clearance mechanisms demonstrated in PD and
AD. Metabolic stress was examined in relation to the current curative properties of EC,
and various anti-oxidative functions of GA were deliberated. The postulated role of EGCG
in mediating cholesterol metabolism was introduced. Lastly, a debated topic of health
disparities, sex, and gender were included to deal with the challenge of unequal access to
curative therapies due to socioeconomic conditions. EGCG remains a promising therapeutic
26 of 35
strategy in the battle against neurodegenerative disease.
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